Contact this trialFirst, we need to learn more about you.
Cancer Vaccine
VGX-3100 + Electroporation for High-Grade Anal Lesions in HIV
Recruiting1 awardPhase 2
Los Angeles, California
This trial studies a DNA vaccine called VGX-3100 combined with a technique to help it enter cells, aiming to treat HIV-positive patients with severe anal lesions caused by HPV. The vaccine helps the immune system attack harmful cells, and the technique makes it easier for the vaccine to enter the cells. This combination aims to improve treatment effectiveness for these patients. VGX-3100 is being developed as an alternative to surgery for treating precancerous disease while preserving reproductive health.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service